Microsatellite Alterations of Plasma DNA in Non-Small Cell Lung Cancer

被引:0
作者
Kim, Kyu-Sik [1 ,2 ]
Kim, Eun-Jung [2 ]
Kim, Soo-Ock [2 ]
Oh, In-Jae [2 ]
Park, Chang-Min [2 ]
Jeong, Ju-Yeon [1 ,2 ]
Kim, Yu-Il [2 ]
Lim, Sung-Chul [2 ]
Park, Jong-Tae [3 ]
Kim, Young-Chul [1 ,2 ]
机构
[1] Chonnam Natl Univ, Hwasun Hosp, Lung & Esophageal Canc Clin, Hwasun, South Korea
[2] Chonnam Natl Univ, Sch Med, Dept Pulmonol & Crit Care Med, Hwasun, South Korea
[3] Chonnam Natl Univ, Sch Med, Dept Forens Med, Hwasun, South Korea
关键词
Non-Small Cell Lung cancer; Microsatellite Alteration; Plasma DNA;
D O I
10.4046/trd.2005.58.4.352
中图分类号
R56 [呼吸系及胸部疾病];
学科分类号
摘要
Microsatellites are short tandem repeated nucleotide sequences that are present throughout the human genome. Variations in the repeat number or a loss of heterozygosity around the microsatellites have been termed a microsatellite alteration (MA). A MA reflects the genetic instability caused by an impairment in the DNA mismatch repair system and is suggested to be a novel tumorigenic mechanism. A number of studies have reported that MA in the DNA extracted from the plasma occurs at varying frequencies among patients with a non-small cell lung carcinoma (NSCLC). The genomic DNA from 9 subjects with a non-small cell lung cancer (squamous cell cancer 6, adenocarcinoma 2, non-small cell lung cancer1) and 9 age matched non-cancer control subjects (AMC: tuberculosis 3, other inflammatory lung disease 6) and 12 normal control subjects (NC) were extracted from the peripheral blood leukocytes and plasma. Three microsatellite loci were amplified with the primers targeting the Gene Bank sequence D21S1245, D3S1300, and D3S1234. MA in the form of an allelic loss or a band shift was examined with 6% polyacrylamide gel electrophoresis and silver staining. None (0/12) of the NC subjects less than 40 years of age showed a MA in any of the three markers, while 88.9%(8/9) of the AMC above 40 showed a MA in at least one of the three markers (p< 0.05). Sixty percent(6/10) of the control subjects with a smoking history showed a MA in one of the three markers, while 9.1%(1/11) of the control subjects without smoking history showed a MA (p< 0.05). However, not only did 66.7%(6/9) of lung cancer patients show a MA in at least one of the three markers but so did 88.9%(8/21) of the AMC patients (p> 0.05). In conclusion, a MA in the D21S1245, D3S1300, and D3S1234 loci using DNA extracted from the plasma was detected in 66.7% of lung cancer while no MA was found in the young non-smoking control subjects. However, many of the non-cancer control subjects (aged smokers) also showed a MA, which compromised the specificity of the MA analysis as a screening test. Therefore, a further study with a larger sample size will be needed.
引用
收藏
页码:352 / 358
页数:7
相关论文
共 50 条
  • [41] Application of Circulating Tumor DNA as a Biomarker for Non-Small Cell Lung Cancer
    Yang, Jialiang
    Hui, Yan
    Zhang, Yanxiang
    Zhang, Minghui
    Ji, Binbin
    Tian, Geng
    Guo, Yangqiang
    Tang, Min
    Li, Lianxing
    Guo, Bella
    Ma, Tonghui
    FRONTIERS IN ONCOLOGY, 2021, 11
  • [42] Molecular evidence of viral DNA in non-small cell lung cancer and non-neoplastic lung
    Lary A Robinson
    Crystal J Jaing
    Christine Pierce Campbell
    Anthony Magliocco
    Yin Xiong
    Genevra Magliocco
    James B Thissen
    Scott Antonia
    British Journal of Cancer, 2016, 115 : 497 - 504
  • [43] Targeting HER2 genomic alterations in non-small cell lung cancer
    Zeng, Jie
    Ma, Weijie
    Young, Richard Benjamin
    Li, Tianhong
    JOURNAL OF THE NATIONAL CANCER CENTER, 2021, 1 (02): : 58 - 73
  • [44] circIARS: a potential plasma biomarker for diagnosing non-small cell lung cancer
    Zhang, Qi
    Fan, Xinfeng
    Zhang, Xinyu
    Ju, Shaoqing
    ACTA BIOCHIMICA ET BIOPHYSICA SINICA, 2024, 56 (06): : 927 - 936
  • [45] Non-small cell lung cancer transdifferentiation into small cell lung cancer: A case series
    Ahmed, Tahreem
    Vial, Macarena R.
    Ost, David
    Stewart, John
    Hasan, Muhammad A.
    Grosu, Horiana B.
    LUNG CANCER, 2018, 122 : 220 - 223
  • [46] Cetuximab in non-small cell lung cancer
    Ademuyiwa, Foluso O.
    Hanna, Nasser
    EXPERT OPINION ON BIOLOGICAL THERAPY, 2008, 8 (01) : 107 - 113
  • [47] Mobocertinib in non-small cell lung cancer
    Liu, Shengwu
    Lowder, Kristen E.
    DRUGS OF TODAY, 2022, 58 (11) : 523 - 530
  • [48] Urine cell-free DNA as a promising biomarker for early detection of non-small cell lung cancer
    Ren, Sai
    Ren, Xiao-Dong
    Guo, Li-Fang
    Qu, Xue-Mei
    Shang, Mei-Yun
    Dai, Xiao-Tian
    Huang, Qing
    JOURNAL OF CLINICAL LABORATORY ANALYSIS, 2020, 34 (08)
  • [49] Genetic instability of microsatellite sequences in non-small cell lung cancers
    Kim, CH
    Yoo, CG
    Han, SK
    Shim, YS
    Kim, YW
    LUNG CANCER, 1998, 21 (01) : 21 - 25
  • [50] Plasma DNA Methylation Analysis in Predicting Short-Term Recurrence of Surgical Patients with Non-small Cell Lung Cancer (NSCLC)
    Ding, Qingqing
    Mu, Yuan
    Pan, Shiyang
    Shu, Yongqian
    Zhang, Shijiang
    Zhang, Bingfeng
    Wang, Hong
    Gao, Li
    Xia, Wenying
    Xu, Jian
    Zhang, Meijuan
    Zhang, Yuanyuan
    Cao, Yan
    Lu, Shan
    CIRCULATING NUCLEIC ACIDS IN PLASMA AND SERUM, 2011, : 47 - 55